Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 1997;17:3208-3214

This Article
Right arrow Full Text
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tschöpl, M.
Right arrow Articles by Jäger, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tschöpl, M.
Right arrow Articles by Jäger, K.
(Arteriosclerosis, Thrombosis, and Vascular Biology. 1997;17:3208-3214.)
© 1997 American Heart Association, Inc.


Articles

Role of Hemostatic Risk Factors for Restenosis in Peripheral Arterial Occlusive Disease After Transluminal Angioplasty

Martin Tschöpl; Dimitrios A. Tsakiris; German A. Marbet; Karl-Heinz Labs; ; Kurt Jäger

From the Division of Angiology, Department of Internal Medicine and Haemostasis Laboratory (D.A.T., G.A.M.), Department of Central Laboratory, University Hospital Basel, Switzerland.

Correspondence to Prof K. Jäger, Head, Division of Angiology, Petersgraben 4, University Hospital, CH-4031 Basel, Switzerland.

Abstract In a prospective study, the role of various hemostatic factors known to be associated with thrombotic risk was investigated in 71 patients with peripheral arterial occlusive disease (PAOD, stages II through IV, Fontaine; aged 68±13 years). Laboratory investigations were done before; 1, 24, and 48 hours after; and 3 and 6 months after percutaneous transluminal angioplasty (PTA). Thirty of 71 (42.3%) patients developed restenosis (>50% reduction of the lumen diameter) at the site of PTA within 6 months, verified by color-coded duplex sonography. Significantly increased levels of thrombin–antithrombin III complexes (P<.01), prothrombin fragments 1+2 (P<.01), and D-dimers (P<.01) were found 1 hour, as well as 24 to 48 hours, after PTA. Fibrinogen (P<.01) and von Willebrand factor (P<.01) were significantly higher 48 hours after PTA. Restenotic patients as a whole had higher plasma fibrinogen (3.46±1.12 versus 2.95±0.62 g/L, P<.01) and C-reactive protein (25.4±46.7 versus 7.9±6.9 mg/L, P<.05) at baseline, as well as higher fibrinogen (P<.05) and prothrombin fragments 1+2 (P<.01) during months 3 to 6 after PTA. There was a nonsignificant tendency for higher values of von Willebrand factor (206±98% versus 184±100%, P=.2) at baseline in patients with restenosis, whereas tissue plasminogen activator, plasminogen activator inhibitor, coagulation screening tests, blood cell counts, and serum lipids showed no significant difference between the two groups. The relative risk for developing restenosis within 6 months while having high fibrinogen (>2.8 g/L) or C-reactive protein at baseline was 2.80 (95% CI: 1.30–6.02, P<.01) and 1.96 (95% CI: 1.07–3.58, P<.05), respectively. Patients with critical limb ischemia (stage III/IV, Fontaine) had significantly higher fibrinogen and von Willebrand factor at repeated points of time, as well as significantly higher C-reactive protein and lower creatinine clearance at entry. In the logistic regression risk factor analysis, baseline plasma fibrinogen, C-reactive protein concentration, and the severity of the arterial disease were significantly predictive of restenosis. Our results indicate that high procoagulant factors and persistent thrombin generation of the hemostatic system might promote restenosis, particularly in patients with extended atherosclerosis. This finding suggests that new treatment strategies should be taken under consideration for patients with PAOD and PTA.


Key Words: peripheral arterial occlusive disease (PAOD) • percutaneous transluminal angioplasty (PTA) • restenosis • hemostasis




This article has been cited by other articles:


Home page
RadiologyHome page
M. Schillinger, M. Exner, W. Mlekusch, M. Haumer, H. Rumpold, R. Ahmadi, S. Sabeti, O. Wagner, and E. Minar
Endovascular Revascularization Below the Knee: 6-month Results and Predictive Value of C-reactive Protein Level
Radiology, May 1, 2003; 227(2): 419 - 425.
[Abstract] [Full Text] [PDF]


Home page
RadiologyHome page
M. Schillinger, M. Exner, W. Mlekusch, H. Rumpold, R. Ahmadi, S. Sabeti, M. Haumer, O. Wagner, and E. Minar
Vascular Inflammation and Percutaneous Transluminal Angioplasty of the Femoropopliteal Artery: Association with Restenosis
Radiology, October 1, 2002; 225(1): 21 - 26.
[Abstract] [Full Text] [PDF]


Home page
QJMHome page
A. Makin, S.H. Silverman, and G.Y.H. Lip
Peripheral vascular disease and Virchow's triad for thrombogenesis
QJM, April 1, 2002; 95(4): 199 - 210.
[Full Text] [PDF]


Home page
Br. J. Radiol.Home page
A D Blann, R Adams, R Ashleigh, S Naser, U Kirkpatrick, and C N McCollum
Changes in endothelial, leucocyte and platelet markers following contrast medium injection during angiography in patients with peripheral artery disease
Br. J. Radiol., September 1, 2001; 74(885): 811 - 817.
[Abstract] [Full Text] [PDF]